We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Batm Advanced Communications Ld | LSE:BVC | London | Ordinary Share | IL0010849045 | ORD ILS0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.96% | 20.60 | 20.00 | 20.60 | 20.60 | 19.80 | 19.95 | 346,632 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Communications Services, Nec | 122.83M | -193k | -0.0004 | -500.00 | 90.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
16/7/2020 22:19 | Listened to the interview-what a lovely, cheerful character. Full of enthusiasm for life. | cumnor | |
16/7/2020 20:51 | >wizz.... Zvi does come out with them. I thought he said the fat lady had sung maybe it was the first verse he was referring to ? At least we know the reason for the share price rise. I am not suggesting BATM are particularly bad about leaks, but a few days prior to any announcement something seems to get out. They are in a closed period. H1 results soon. Another area of major co operation and development. | fse | |
16/7/2020 15:21 | Randox test just been pulled,as no good in UK batm need to put there foot in the door and blow ncyt out the water aswell while there at it ? | markyt | |
16/7/2020 14:36 | the fat lady is yet to sing...<;-) | wizzkid211 | |
16/7/2020 13:20 | Twitter feed is normally an indicator of news to be released.Latest post:Indian government revises biomedical waste disposal guidelines in response to #COVID19Indicating contract with India???? Otherwise a random post and link. | paulisi | |
16/7/2020 07:57 | What a great communicator he is. Always a twinkle in the eye. I could listen to him for hours. | amt | |
16/7/2020 06:56 | Not so much like a kid who's discovered sweets, more like a kid who's been given a free run of the sweet factory | ianguerin | |
15/7/2020 22:43 | This is serious news and, technically, puts BATM's infectious disease platforms up there with the best. The case for a split of what are two very significant businesses coming to fruition at the right time is hardening. There will be a significant rerating if they do split. Well done BVC and Zvi. | cumnor | |
15/7/2020 22:38 | Very very positive interview. He's like a kid who's just discovered sweets. I suspect the numbers are going to look very good. | rawdeal1 | |
15/7/2020 16:31 | Yes there is a lot to like about this major upgrade which will not just test for various infectious diseases but will provide valuable information to research in producing treatments. IMO successful treatment of the conditions is going to be a more likely outcome than a vaccine in the longer term which is like hitting a moving target with your eyes closed. What I really like about this is the recognition that its not just about Covid19 there are a myriad of other existing and potentially far more dangerous pathogens out there. Its major news as this will allow the company to expand, hire research staff and get up to a critical mass where they can take on the large Pharmas head on. Impressive to say the least. | fse | |
15/7/2020 15:20 | Another excellent interview - well worth listening to.Key points:These tests available on all platforms now not just Aldaltis specific.Expecting to break into the US marketProjected turnover cannot be announced due to closed period, but shareholders should be excitedHome test kits should be ready end Q3/ early Q4. | paulisi | |
15/7/2020 15:04 | Here's this morning's exiting interview with Zvi: Zvi Marom speaks to Proactive London's Andrew Scott following the launch of three new diagnostic kits for coronavirus and other respiratory illnesses. Marom expects to begin sale and production of the kits at its Adaltis facility in Italy at the end of the third and start of the fourth quarter of 2020. | deltaham | |
15/7/2020 13:42 | There is no doubt about it that having the ability to identify different respiratory viruses in one hit is key. When the patient turns up with viral symptoms & temperature etc, you need to be able to differentiate between coronavirus and the others, as management will differ significantly. | rawdeal1 | |
15/7/2020 13:27 | This is excellent news. There is now strong evidence circulating that there may well be a strong second 'spike' of Covid 19 during the winter months as people spend more time indoors.As WHO suggest TEST TEST TEST.More testing kits are desperate needed for 'third world countries'. | 1sjb | |
15/7/2020 13:15 | hxxps://www.news-med | doccash | |
15/7/2020 07:49 | Everything this company does is bang on the right place the right time at mo fantastic | markyt | |
15/7/2020 07:25 | RNS releasedBigger better and more accurate testing designed. Awaiting CE approval. | paulisi | |
15/7/2020 00:36 | Nice mention on news at 10 about nokia /ericssen 5g maybe stepping up to the 5g tech replacement of Huawei | markyt | |
14/7/2020 18:06 | The current benches in labs can test up to 400 in one go. These are part of the mobile labs that go around the UK.No reason why these cannot be scaled up.Airports would be an ideal location due to volumes and time before boarding. | paulisi | |
14/7/2020 17:33 | These are the only two posts on the official twitter account since 30 June.Both related to testing/antibodies from Covid.To be honest, the PR company seem to be new and are trawling the internet for articles that may be related. | paulisi | |
14/7/2020 17:17 | My thoughts exactly would have thought a speculative rise today on it not a drop the slow recovery | markyt | |
14/7/2020 17:06 | If you want something to speculate about then latest UK advice on Huawei leaves the door open for Nokia a company Telco has been involved with for ages in good and tricky times. As far as I know they maintain close connections with them. Now add in ARM Neoverse and Telco NFVTime. There are a lot of synergies there and indirectly associated revenue streams. We could well have our eyes on the wrong ball !! | fse | |
14/7/2020 17:00 | I would not get too excited about Covid19 test kits .... the reporting on the virus with absurd conclusions is so far wide of the mark that its not even worth discussing. Back to reality and where I do feel BATM are getting traction is with their encompassing approach to dealing with "All" infectious diseases from Animal Processing, Airport waste disposal, in situ testing for a variety of diseases, instant testing for specific disease strains, serology testing ...... and if all of that fails then a last shot on an advanced ventilator. BATM have tied all this together for this outbreak and future ones. I have maintained for a very long time that these bench top reader/analyzers and the repeat reagent sales are a high growth area. The company was long overdue for a rerating and we had a recent update from the company that they are on track. There does appear to be increased support from Israeli based investors maybe for the above reasons ? | fse | |
14/7/2020 16:44 | Fascinated to know how a test can test 100,000 individuals simultaneously. I must be misunderstanding the word "simultaneously" | car1pet | |
14/7/2020 16:40 | This is the key piece of the Israeli article - I'm not sure if paragraph 2 relates to BATM or not as there is a picture in between.The biomed division of technology company BATM, for example, which is based in Hod Hasharon and has labs in several countries, is well known for infectious diseases diagnostics. By May 2020, the company had already produced several tests that can diagnose the coronavirus and is now working on a home test kit with Israeli life sciences company Novamedis.?Source: Start-Up Nation CentralA team of researchers at Hebrew University developed what they say is a cheaper and quicker test for the virus. The team is now developing a test that would enable testing 10,000 to 100,000 individuals simultaneously. | paulisi |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions